Trials / No Longer Available
No Longer AvailableNCT04667234
Expanded Access of Sotorasib
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 510 | Administered as an oral tablet. |
Timeline
- First posted
- 2020-12-14
- Last updated
- 2025-08-13
Locations
55 sites across 6 countries: United States, Argentina, Brazil, Israel, Saudi Arabia, Taiwan
Source: ClinicalTrials.gov record NCT04667234. Inclusion in this directory is not an endorsement.